I-Mab (NASDAQ:IMAB) Short Interest Update

I-Mab (NASDAQ:IMAB) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totalling 904,000 shares, an increase of 31.9% from the December 15th total of 685,600 shares. Based on an average daily volume of 477,100 shares, the short-interest ratio is presently 1.9 days.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of I-Mab in a research note on Friday, November 15th.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of IMAB. XTX Topco Ltd boosted its holdings in I-Mab by 140.8% in the 3rd quarter. XTX Topco Ltd now owns 43,039 shares of the company’s stock valued at $53,000 after purchasing an additional 25,163 shares during the last quarter. Caligan Partners LP increased its holdings in shares of I-Mab by 3.7% during the 3rd quarter. Caligan Partners LP now owns 3,499,330 shares of the company’s stock worth $4,339,000 after buying an additional 124,539 shares during the last quarter. Garden State Investment Advisory Services LLC purchased a new stake in shares of I-Mab during the 3rd quarter valued at approximately $179,000. Finally, Bank of Montreal Can acquired a new position in I-Mab in the second quarter valued at approximately $453,000. 38.38% of the stock is owned by hedge funds and other institutional investors.

I-Mab Trading Down 2.7 %

Shares of NASDAQ IMAB opened at $1.07 on Friday. I-Mab has a 52 week low of $0.84 and a 52 week high of $2.08. The firm has a 50-day simple moving average of $0.99 and a 200-day simple moving average of $1.16.

About I-Mab

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.